{
  "abstract": "Background/aims Evaluation of durability outcomes after switching to aflibercept 8 mg for macular oedema in retinal vein occlusion (RVO).Methods We evaluated eyes with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), switching from other anti-vascular endothelial growth factor treatments to off-label aflibercept 8 mg under an observe-and-plan regimen. Eyes receiving ongoing treatment with ≥10 prior injections were eligible. Treatment discontinuation during the 12-month follow-up period resulted in exclusion. All data were obtained through the review of medical records.Results The overall cohort of eyes with RVO (n=156) achieved a mean interval gain of +1.6 weeks at 12 months (p<0.0001). The proportion of eyes treated at ≤6-week intervals decreased from 37.8% at switch to 17.9% at 12-month follow-up (p<0.0001) while the proportion on intervals ≥9 weeks increased from 37.8% at switch to 60.3% (p<0.0001). The CRVO subgroup (n=65) achieved a mean increase in interval length at 12 months of +2.0 weeks (p<0.0001) and +3.0 weeks in the case of a dry macula at switch (p<0.0001). The BRVO subgroup (n=91) achieved an overall increase in interval length of +1.3 weeks (p<0.0001) and +2.3 weeks for eyes with a dry macula at switch (p<0.0001). The central retinal thickness decreased from 262.8±79.4 µm to 244.6±59.5 µm (p=0.0012) while best recorded visual acuity remained unchanged at 68.2 Early Treatment Diabetic Retinopathy Study letters at 12 months.Conclusion Switching to aflibercept 8 mg substantially reduced the proportion of eyes on short intervals without compromising visual outcomes.",
  "authors": [
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Chi Tuyet Nguyen"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Rasmus Klock Bøgh Lassen"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Mads Odgaard Mæng"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Celine Lee"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Rigshospitalet, Copenhagen, Capital Region of Denmark, Denmark",
        "Department of Ophthalmology, University of Southern Denmark, Odense, Denmark"
      ],
      "name": "Yousif Subhi"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Henrik Vorum"
    },
    {
      "affiliations": [
        "Retina Consultants of Texas, Houston, Texas, USA"
      ],
      "name": "Charles C Wykoff"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark"
      ],
      "name": "Marie Ørskov"
    },
    {
      "affiliations": [
        "Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark",
        "Department of Clinical Medicine, Aalborg University, Aalborg, Denmark",
        "Retina Consultants of Texas, Houston, Texas, USA"
      ],
      "name": "Lasse Jørgensen Cehofski"
    }
  ],
  "title": "Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes",
  "uid": "647c845c-88a1-581e-b6b7-eb6e2e6ea391"
}